Premium Nahrungsergänzungsmittel | artgerecht

Midostaurin - Mechanism, Uses & Side Effects

Midostaurin is a targeted cancer medicine used to treat acute myeloid leukemia and systemic mastocytosis. It blocks specific enzymes that drive tumor growth.

Regular tips about health Regular tips about health

Things worth knowing about "Midostaurin"

Midostaurin is a targeted cancer medicine used to treat acute myeloid leukemia and systemic mastocytosis. It blocks specific enzymes that drive tumor growth.

What is Midostaurin?

Midostaurin (brand name: Rydapt) is a kinase inhibitor (tyrosine kinase inhibitor) used in oncology as a targeted therapy. It has been approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Midostaurin belongs to the class of multi-kinase inhibitors, meaning it interferes with several signaling pathways that drive the uncontrolled growth of cancer cells.

Approved Indications

Midostaurin is approved for two main conditions:

Acute myeloid leukemia (AML) with FLT3 mutation: In combination with standard induction chemotherapy (daunorubicin and cytarabine) in adult patients with newly diagnosed AML in whom a FLT3 gene mutation (Fms-like tyrosine kinase 3) has been detected.
Systemic mastocytosis: As monotherapy in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

Mechanism of Action

Midostaurin acts as a multi-kinase inhibitor, simultaneously blocking multiple enzymes (kinases) that regulate the growth and survival of tumor cells. The key molecular targets include:

FLT3 (Fms-like tyrosine kinase 3): In AML patients harboring a FLT3 mutation, excessive FLT3 activity leads to uncontrolled proliferation of leukemia cells. Midostaurin inhibits both the FLT3-ITD and FLT3-TKD mutations.
KIT (CD117): Systemic mastocytosis is frequently driven by an activating mutation in the KIT gene (D816V), causing uncontrolled mast cell proliferation. Midostaurin inhibits this mutated KIT kinase, thereby reducing mast cell growth.
PDGFRα and PDGFRβ (Platelet-derived growth factor receptors): Additional targets that contribute to the antitumor effect.
VEGFR2 (Vascular endothelial growth factor receptor 2): Inhibition of new blood vessel formation within tumors (antiangiogenic effect).

By simultaneously targeting multiple kinases, midostaurin acts on several levels of tumor biology, making it more broadly effective than selective single-kinase inhibitors.

Dosage and Administration

Midostaurin is taken orally as a soft gelatin capsule. The standard dose is 50 mg twice daily (morning and evening), always taken with food to improve tolerability and optimize absorption.

In AML: Midostaurin is taken on days 8 to 21 of each chemotherapy cycle (induction and consolidation therapy) and during a subsequent maintenance phase.
In systemic mastocytosis: Midostaurin is taken continuously until disease progression or the occurrence of unacceptable side effects.

Side Effects

Like all targeted cancer therapies, midostaurin can cause side effects that vary in intensity and should be monitored by a physician.

Common Side Effects

Nausea, vomiting, and diarrhea
Headache and fatigue
Edema (fluid retention)
Fever and infections (due to immunosuppression)
Changes in blood count values (leukopenia, thrombocytopenia, anemia)

Serious Side Effects

Interstitial lung disease / pneumonitis: Inflammatory changes in the lungs requiring close monitoring.
QT prolongation: Changes in heart rhythm (ECG monitoring is recommended).
Severe infections: Due to immune system suppression.
Embryo-fetal toxicity: Midostaurin must not be taken during pregnancy. Effective contraception is required during treatment and for at least 4 months after the last dose.

Drug Interactions

Midostaurin is metabolized primarily by the enzyme CYP3A4 in the liver. Therefore, interactions with other medicines that affect this enzyme must be considered:

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) increase midostaurin blood levels and may intensify side effects.
Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, St. John's wort) lower blood levels and may reduce efficacy.

Important Notes

Treatment with midostaurin should only be initiated and supervised by a physician experienced in oncology.
A FLT3 mutation test is required before starting therapy in AML patients.
Regular blood count and liver function monitoring is necessary during treatment.
Breastfeeding is not recommended during treatment and for at least 4 months after the last dose.

References

European Medicines Agency (EMA): Rydapt (midostaurin) - Product Information and Assessment Report. EMA/CHMP, 2017. Available at: https://www.ema.europa.eu
Stone RM et al. - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine, 2017; 377(5): 454-464. DOI: 10.1056/NEJMoa1614359
Gotlib J et al. - Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. New England Journal of Medicine, 2016; 374(26): 2530-2541. DOI: 10.1056/NEJMoa1513098

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.